A A A

John Snisarenko

John Snisarenko

John Snisarenko has been a member of our board of directors since July 2019. Mr. Snizarenko has more than 30 years of commercial experience in the pharmaceutical industry, including major retina and ophthalmology businesses. Mr. Snisarenko joined Shire (now Takeda) in 2017 as Group Vice President and Head of its ophthalmic business. and played a key role in the divestiture of the ophthalmic business to Novartis Pharma. Prior to joining Shire, Mr. Snisarenko led commercial activities for Genentech’s ophthalmology (Lucentis®) and rheumatology (Rituxan®, Actemra®) franchises for 10 years. Mr. Snisarenko also held various positions of increasing responsibility at CIBA Vision/Novartis Pharma. Mr. Snisarenko has held numerous advisory board positions and was a board member for the Foundation Fighting Blindness in Canada. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.
Independent Director